

AMICUS THERAPEUTICS INC  
 Form 3  
 May 30, 2007

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â Ludwig Karin  
 (Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)  
 05/30/2007

3. Issuer Name and Ticker or Trading Symbol

AMICUS THERAPEUTICS INC [FOLD]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 Senior VP, Clinical Research

5. If Amendment, Date Original Filed(Month/Day/Year)

C/O AMICUS THERAPEUTICS, INC.,Â 6 CEDAR BROOK DRIVE

(Street)

CRANBURY,Â NJÂ 08512

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable Date Expiration Date

Title Amount or Number of

Edgar Filing: AMICUS THERAPEUTICS INC - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	02/28/2016	Common Stock	60,000	\$ 5.33	D	Â
Employee Stock Option (right to buy)	Â (2)	02/28/2016	Common Stock	6,667	\$ 5.33	D	Â
Employee Stock Option (right to buy)	Â (3)	04/25/2017	Common Stock	40,000	\$ 13.43	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ludwig Karin C/O AMICUS THERAPEUTICS, INC. 6 CEDAR BROOK DRIVE CRANBURY, NJ 08512	Â	Â	Â Senior VP, Clinical Research	Â

## Signatures

/s/ Douglas A. Branch,  
Attorney-in-fact

05/30/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 21, 2007. The remaining options vest and become exercisable in a series of thirty-six successive equal monthly installments, beginning on March 1, 2007.

(2) These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 28, 2007. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 139 shares, beginning on March 1, 2007, with the final installment of 135 shares becoming exercisable on February 1, 2010.

(3) These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, will vest on April 25, 2008. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 834 shares, beginning on May 1, 2008, with the final installment of 810 shares becoming exercisable on April 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.